Phathom Pharmaceuticals PHAT
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 4th percentile, 5-year average -2.5x
Above its usual level · 76th percentile, 5-year average -5.7x
Around its usual level · 47th percentile, 5-year average 50.1x
#2396 of 5156 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | -1.42 | – | -5.72 | 76% (pricier than usual) | – |
| PE | -6.00 | 99.02 | -2.49 | 4% (cheaper than usual) | – |
| PS | 1.79 | 1.13 | 50.07 | 47% (cheaper than usual) | #2396 of 5156 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on PHAT.
Sign in to join the discussion.